When the Centers for Disease Control and Prevention (CDC) released its 2022 STI surveillance report, it was far from a clean ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

The FDA starts priority review of GSK's gepotidacin, vying to become the first new-class antibiotic for uncomplicated urinary tract infections in over 20 years.

GSK's novel antibiotic gepotidacin matches current therapy in gonorrhoea, raising hope of new oral therapy as cases of the infection rise worldwide.

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GSK’s pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection (“UTI”) were approved in the United States in the first quarter of ...

PHILADELPHIA, PA — The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections ...

Get the latest GlaxoSmithKline plc (GSK) stock news and headlines to help you in your trading and investment decisions.

The Santa Clarita Valley Signal is the #1 source for local news in the Santa Clarita Valley area since 1919.

The latest international news, investigations and analysis from Africa, the Americas, Asia, Australia, Canada, Europe, the Middle East and the U.K.